NFKB1 and squamous cell lung carcinoma: Ruiz et al. showed that lung squamous cell carcinoma (LSCC) tumors were resistant to the chemotherapeutic agent cisplatin due to the higher expression of LUBAC and higher activity of NF-κB [48].